Danazol but not gonadotropin-releasing hormone agonists suppresses autoantibodies in endometriosis.

Abstract

The effect of treatment with danazol (n = 10) or gonadotropin-releasing hormone agonists (GnRH-a) (n = 10) on autoantibody (AA) production (IgG, IgM and, IgA to 6 phospholipids, 5 histones, and 4 polynucleotides) in endometriosis was evaluated blindly in a longitudinal, prospective, randomized study. Clinical improvement, ovarian suppression, and resolution of endometriosis were comparable in both groups. Approximately 50% of patients had significant AA abnormalities initially. During treatment with danazol but not GnRH-a, AA gradually decreased in concentration and in number/patient. Total immunoglobulin levels (IgG, IgM, and IgA) also decreased only in the danazol group. This study indicates that danazol, but not GnRH-a, lowers abnormal AA associated with endometriosis.

• Authors: A el-Roeiy, W P Dmowski, N Gleicher, E Radwanska, L Harlow, Z Binor, I Tummon, R G Rawlins
• Journal: Fertility and sterility (Fertil Steril) Vol. 50 Issue 6 Pg. 864-71 (Dec 1988) ISSN: 0015-0282 [Print] United States
• PMID: 3060379 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Autoantibodies
• Immunoglobulins
• Pituitary Hormone-Releasing Hormones
• Pregnadienes
• Danazol

Topics

• Adult
• Antibody Formation (drug effects)
• Autoantibodies (analysis)
• Danazol (pharmacology)
• Depression, Chemical
• Endometriosis (immunology)
• Female
• Humans
• Immunoglobulins (analysis)
• Pituitary Hormone-Releasing Hormones (pharmacology)
• Pregnadienes (pharmacology)
• Pregnancy
• Pregnancy Outcome
• Random Allocation